This approach could also allow for a non-MHC-restricted recognition of diverse tumor targets through either the CAR NK-cell activating receptors or endogenous TCR receptors of NKT cells triggered by glycolipids presented via CD1d, improving the effector cells’ resistance to exhaustion. Here, CD1D is linked to neoplasm.